NRx Pharmaceuticals sets Dec. 17, 2026 virtual annual meeting; submission deadlines Oct. 25–26

NRx Pharmaceuticals received FDA approval for its Preservative-Free Ketamine, ahead of the November 10 goal date. The product, manufactured in the U.S., contains no benzethonium chloride and is now available for hospitals and clinics. Ketamine has been in short supply since 2018, according to the company.

NRX Pharmaceuticals, Inc. (NRXP) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date October 30, 2026 ● Preservative-Free Ketamine is an American-manufactured presentation of ketamine that contains no benzethonium chloride (BZT), a

NRx Pharmaceuticals (NASDAQ:NRXP) received FDA approval for its preservative-free ketamine injection, addressing a national drug shortage. The company's manufacturing technology allows for faster production. NRx plans to target hospitals, wholesalers, and clinics, with initial focus on converting top-tier hospital customers. The company expects to introduce additional ketamine products in 2027 and is developing other CNS treatments, including NRX-101 for bipolar depression.

NRX Pharmaceuticals' stock rose 14.3% in pre-market trading after FDA approval of its Preservative-Free Ketamine, ahead of the expected November 10 date. The company completed pre-launch manufacturing requirements and received an $11.25 million DARPA contract for a Phase 3 trial of NRX-101. CEO Jonathan Javitt expressed excitement about the market launch.

NRx Pharmaceuticals (NRXP) received FDA approval for its preservative-free ketamine injection, ahead of the November 10 target date. The company claims the formulation addresses concerns about potential toxicity from the preservative BZT. NRx has supply ready for U.S. distribution and is manufacturing the product with Nephron Pharmaceuticals. The stock was up 16.60% in pre-market trading.

NRx Pharmaceuticals (NRXP) gained over 15% premarket after FDA approved its generic ketamine injection, addressing U.S. supply shortages for pain and anesthesia treatment.